Aspirin therapy reduces the ability of platelets to promote colon and pancreatic cancer cell proliferation: Implications for the oncoprotein c-MYC

American Journal of Physiology - Cell Physiology

Volumn 312, Issue 2, 2017, Pages C176-C189

  Mitrugno, Annachiara ^a,b,c   Sylman, Joanna L ^a   Ngo, Anh T P ^a   Pang, Jiaqing ^a   Sears, Rosalie C ^b,c   Williams, Craig D ^b,d   McCarty, Owen J T ^a,b,c  

^a Oregon Health and Science University Department of Biomedical Engineering   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d OREGON STATE UNIVERSITY   (United States)

Author keywords

Aspirin; C MYC; Cancer; Platelets; Proliferation

Indexed keywords

ACETYLSALICYLIC ACID; MYC PROTEIN; ANTITHROMBOCYTIC AGENT; ONCOPROTEIN;

ADENOCARCINOMA CELL LINE; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CELL INTERACTION; COLON ADENOCARCINOMA; COLON CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; IN VITRO STUDY; PANC 1 CELL LINE; PANCREAS CANCER; PANCREATIC CANCER CELL LINE; PRIORITY JOURNAL; SW480 CELL LINE; SW620 CELL LINE; THROMBOCYTE; UPREGULATION; CARCINOGENESIS; CELL COMMUNICATION; CELL PROLIFERATION; COLONIC NEOPLASMS; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; PANCREATIC NEOPLASMS; PATHOLOGY; TREATMENT OUTCOME; TUMOR CELL LINE;

ASPIRIN; BLOOD PLATELETS; CARCINOGENESIS; CELL COMMUNICATION; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; ONCOGENE PROTEINS; PANCREATIC NEOPLASMS; PLATELET AGGREGATION INHIBITORS; TREATMENT OUTCOME;

EID: 85012066256     PISSN: 03636143     EISSN: 15221563     Source Type: Journal    
DOI: 10.1152/ajpcell.00196.2016     Document Type: Article

References (46)

1. Ai G, Dachineni R, Muley P, Tummala H, Bhat GJ. Aspirin and salicylic acid decrease c-Myc expression in cancer cells: A potential role in chemoprevention. Tumour Biol 37: 1727–1738, 2016. doi:10.1007/s13277-015-3959-0.
2. Armstrong PC, Truss NJ, Ali FY, Dhanji AA, Vojnovic I, Zain ZN, Bishop-Bailey D, Paul-Clark MJ, Tucker AT, Mitchell JA, Warner TD. Aspirin and the in vitro linear relationship between thromboxane A2-mediated platelet aggregation and platelet production of thromboxane A2. J Thromb Haemost 6: 1933–1943, 2008. doi:10.1111/j.1538-7836.2008.03133.x.
3. Aslan JE, Tormoen GW, Loren CP, Pang J, McCarty OJ. S6K1 and mTOR regulate Rac1-driven platelet activation and aggregation. Blood 118: 3129–3136, 2011. doi:10.1182/blood-2011-02-331579.
4. Baker-Groberg SM, Itakura A, Gruber A, McCarty OJ. Role of coagulation in the recruitment of colon adenocarcinoma cells to thrombus under shear. Am J Physiol Cell Physiol 305: C951–C959, 2013. doi:10.1152/ajpcell.00185.2013.
5. Battinelli EM, Markens BA, Italiano JE Jr. Release of angiogenesis regulatory proteins from platelet alpha granules: Modulation of physiologic and pathologic angiogenesis. Blood 118: 1359–1369, 2011. doi:10.1182/blood-2011-02-334524.
6. Birnbaum DJ, Adélaïde J, Mamessier E, Finetti P, Lagarde A, Monges G, Viret F, Gonçalvès A, Turrini O, Delpero JR, Iovanna J, Giovannini M, Birnbaum D, Chaffanet M. Genome profiling of pancreatic adenocarcinoma. Genes Chromosomes Cancer 50: 456–465, 2011. doi:10.1002/gcc.20870.
7. Bowles DW, Jimeno A. New phosphatidylinositol 3-kinase inhibitors for cancer. Expert Opin Investig Drugs 20: 507–518, 2011. doi:10.1517/13543784.2011.562192.
8. Chiariello M, Marinissen MJ, Gutkind JS. Regulation of c-myc expression by PDGF through Rho GTPases. Nat Cell Biol 3: 580–586, 2001. doi:10.1038/35078555.
9. Cho MS, Bottsford-Miller J, Vasquez HG, Stone R, Zand B, Kroll MH, Sood AK, Afshar-Kharghan V. Platelets increase the proliferation of ovarian cancer cells. Blood 120: 4869–4872, 2012. doi:10.1182/blood-2012-06-438598.
10. Choi SH, Smith SA, Morrissey JH. Polyphosphate is a cofactor for the activation of factor XI by thrombin. Blood 118: 6963–6970, 2011. doi: 10.1182/blood-2011-07-368811.
11. Cooke NM, Spillane CD, Sheils O, O’Leary J, Kenny D. Aspirin and P2Y12 inhibition attenuate platelet-induced ovarian cancer cell invasion. BMC Cancer 15: 627, 2015. doi:10.1186/s12885-015-1634-x.
12. Coppinger JA, O’Connor R, Wynne K, Flanagan M, Sullivan M, Maguire PB, Fitzgerald DJ, Cagney G. Moderation of the platelet releasate response by aspirin. Blood 109: 4786–4792, 2007. doi:10.1182/blood-2006-07-038539.
13. Dovizio M, Tacconelli S, Sostres C, Ricciotti E, Patrignani P. Mechanistic and pharmacological issues of aspirin as an anticancer agent. Pharmaceuticals (Basel) 5: 1346–1371, 2012. doi:10.3390/ph5121346.
14. Erisman MD, Rothberg PG, Diehl RE, Morse CC, Spandorfer JM, Astrin SM. Deregulation of c-myc gene expression in human colon carcinoma is not accompanied by amplification or rearrangement of the gene. Mol Cell Biol 5: 1969–1976, 1985. doi:10.1128/MCB.5.8.1969.
15. Faiola F, Liu X, Lo S, Pan S, Zhang K, Lymar E, Farina A, Martinez E. Dual regulation of c-Myc by p300 via acetylation-dependent control of Myc protein turnover and coactivation of Myc-induced transcription. Mol Cell Biol 25: 10220–10234, 2005. doi:10.1128/MCB.25.23.10220-10234.2005.
16. Ho-Tin-Noé B, Goerge T, Cifuni SM, Duerschmied D, Wagner DD. Platelet granule secretion continuously prevents intratumor hemorrhage. Cancer Res 68: 6851–6858, 2008. doi:10.1158/0008-5472.CAN-08-0718.
17. Huang MJ, Cheng YC, Liu CR, Lin S, Liu HE. A small-molecule c-Myc inhibitor, 10058-F4, induces cell-cycle arrest, apoptosis, and myeloid differentiation of human acute myeloid leukemia. Exp Hematol 34: 1480–1489, 2006. doi:10.1016/j.exphem.2006.06.019.
18. Jones CM, Baker-Groberg SM, Cianchetti FA, Glynn JJ, Healy LD, Lam WY, Nelson JW, Parrish DC, Phillips KG, Scott-Drechsel DE, Tagge IJ, Zelaya JE, Hinds MT, McCarty OJ. Measurement science in the circulatory system. Cell Mol Bioeng 7: 1–14, 2014. doi:10.1007/s12195-013-0317-4.
19. Kelly K, Cochran BH, Stiles CD, Leder P. Cell-specific regulation of the c-myc gene by lymphocyte mitogens and platelet-derived growth factor. Cell 35: 603–610, 1983. doi:10.1016/0092-8674(83)90092-2.
20. King MR, Phillips KG, Mitrugno A, Lee TR, de Guillebon AM, Chandrasekaran S, McGuire MJ, Carr RT, Baker-Groberg SM, Rigg RA, Kolatkar A, Luttgen M, Bethel K, Kuhn P, Decuzzi P, McCarty OJ. A physical sciences network characterization of circulating tumor cell aggregate transport. Am J Physiol Cell Physiol 308: C792–C802, 2015. doi:10.1152/ajpcell.00346.2014.
21. Knoepfler PS. Myc goes global: New tricks for an old oncogene. Cancer Res 67: 5061–5063, 2007. doi:10.1158/0008-5472.CAN-07-0426.
22. Kopp HG, Placke T, Salih HR. Platelet-derived transforming growth factor-beta down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity. Cancer Res 69: 7775–7783, 2009. doi:10.1158/0008-5472.CAN-09-2123.
23. Labelle M, Begum S, Hynes RO. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell 20: 576–590, 2011. doi:10.1016/j.ccr.2011.09.009.
24. Labelle M, Begum S, Hynes RO. Platelets guide the formation of early metastatic niches. Proc Natl Acad Sci USA 111: E3053–E3061, 2014. doi:10.1073/pnas.1411082111.
25. Lai MY, Huang JA, Liang ZH, Jiang HX, Tang GD. Mechanisms underlying aspirin-mediated growth inhibition and apoptosis induction of cyclooxygenase-2 negative colon cancer cell line SW480. World J Gastroenterol 14: 4227–4233, 2008. doi:10.3748/wjg.14.4227.
26. Leibovitz A, Stinson JC, McCombs WB III, McCoy CE, Mazur KC, Mabry ND. Classification of human colorectal adenocarcinoma cell lines. Cancer Res 36: 4562–4569, 1976.
27. Liu G, Campbell BT, Holladay MW, Ford Pulido JM, Hua H, Gitnick D, Gardner MF, James J, Breider MA, Brigham D, Belli B, Armstrong RC, Treiber DK. Discovery of AC710, a globally selective inhibitor of platelet-derived growth factor receptor-family kinases. ACS Med Chem Lett 3: 997–1002, 2012. doi:10.1021/ml300214g.
28. McCarty OJ, Jadhav S, Burdick MM, Bell WR, Konstantopoulos K. Fluid shear regulates the kinetics and molecular mechanisms of activation-dependent platelet binding to colon carcinoma cells. Biophys J 83: 836–848, 2002. doi:10.1016/S0006-3495(02)75212-0.
29. McCarty OJ, Mousa SA, Bray PF, Konstantopoulos K. Immobilized platelets support human colon carcinoma cell tethering, rolling, and firm adhesion under dynamic flow conditions. Blood 96: 1789–1797, 2000.
30. Menter DG, Tucker SC, Kopetz S, Sood AK, Crissman JD, Honn KV. Platelets and cancer: A casual or causal relationship: revisited. Cancer Metastasis Rev 33: 231–269, 2014. doi:10.1007/s10555-014-9498-0.
31. Mitrugno A, Tormoen GW, Kuhn P, McCarty OJ. The prothrombotic activity of cancer cells in the circulation. Blood Rev 30: 11–19, 2016. doi:10.1016/j.blre.2015.07.001.
32. Mitrugno A, Williams D, Kerrigan SW, Moran N. A novel and essential role for FcRIIa in cancer cell-induced platelet activation. Blood 123: 249–260, 2014. doi:10.1182/blood-2013-03-492447.
33. Phillips KG, Kuhn P, McCarty OJ. Physical biology in cancer. 2. The physical biology of circulating tumor cells. Am J Physiol Cell Physiol 306: C80–C88, 2014. doi:10.1152/ajpcell.00294.2013.
34. Phillips KG, Lee AM, Tormoen GW, Rigg RA, Kolatkar A, Luttgen M, Bethel K, Bazhenova L, Kuhn P, Newton P, McCarty OJ. The thrombotic potential of circulating tumor microemboli: Computational modeling of circulating tumor cell-induced coagulation. Am J Physiol Cell Physiol 308: C229–C236, 2015. doi:10.1152/ajpcell.00315.2014.
35. Agus DB, Alexander JF, Arap W, Ashili S, Aslan JE, Austin RH, Backman V, Bethel KJ, Bonneau R, Chen WC, Chen-Tanyolac C, Choi NC, Curley SA, Dallas M, Damania D, Davies PC, Decuzzi P, Dickinson L, Estevez-Salmeron L, Estrella V, Ferrari M, Fischbach C, Foo J, Fraley SI, Frantz C, Fuhrmann A, Gascard P, Gatenby RA, Geng Y, Gerecht S, Gillies RJ, Godin B, Grady WM, Greenfield A, Hemphill C, Hempstead BL, Hielscher A, Hillis WD, Holland EC, Ibrahim-Hashim A, Jacks T, Johnson RH, Joo A, Katz JE, Kelbauskas L, Kesselman C, King MR, Konstantopoulos K, Kraning-Rush CM, Kuhn P, Kung K, Kwee B, Lakins JN, Lambert G, Liao D, Licht JD, Liphardt JT, Liu L, Lloyd MC, Lyubimova A, Mallick P, Marko J, McCarty OJ, Meldrum DR, Michor F, Mumenthaler SM, Nandakumar V, O’Halloran TV, Oh S, Pasqualini R, Paszek MJ, Philips KG, Poultney CS, Rana K, Reinhart-King CA, Ros R, Semenza GL, Senechal P, Shuler ML, Srinivasan S, Staunton JR, Stypula Y, Subramanian H, Tlsty TD, Tormoen GW, Tseng Y, van Oudenaarden A, Verbridge SS, Wan JC, Weaver VM, Widom J, Will C, Wirtz D, Wojtkowiak J, Wu PH; Physical Sciences-Oncology Centers Network. A physical sciences network characterization of non-tumorigenic and metastatic cells. Sci Rep 3: 1449, 2013. doi:10.1038/srep01449.
36. Placke T, Kopp HG, Salih HR. Modulation of natural killer cell antitumor reactivity by platelets. J Innate Immun 3: 374–382, 2011. doi:10.1159/000323936.
37. Powis G, Bonjouklian R, Berggren MM, Gallegos A, Abraham R, Ashendel C, Zalkow L, Matter WF, Dodge J, Grindey G, Vlahos CJ. Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase. Cancer Res 54: 2419–2423, 1994.
38. Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z. Effect of daily aspirin on risk of cancer metastasis: A study of incident cancers during randomised controlled trials. Lancet 379: 1591–1601, 2012. doi:10.1016/S0140-6736(12)60209-8.
39. Schmidt EV. The role of c-myc in cellular growth control. Oncogene 18: 2988–2996, 1999. doi:10.1038/sj.onc.1202751.
40. Schumacher D, Strilic B, Sivaraj KK, Wettschureck N, Offermanns S. Platelet-derived nucleotides promote tumor-cell transendothelial migration and metastasis via P2Y2 receptor. Cancer Cell 24: 130–137, 2013. doi:10.1016/j.ccr.2013.05.008.
41. Sears RC, Nevins JR. Signaling networks that link cell proliferation and cell fate. J Biol Chem 277: 11617–11620, 2002. doi:10.1074/jbc.R100063200.
42. Shirakawa K, Wang L, Man N, Maksimoska J, Sorum AW, Lim HW, Lee IS, Shimazu T, Newman JC, Schröder S, Ott M, Marmorstein R, Meier J, Nimer S, Verdin E. Salicylate, diflunisal and their metabolites inhibit CBP/p300 and exhibit anticancer activity. eLife 5: 5, 2016. doi:10.7554/eLife.11156.
43. Thun MJ, Jacobs EJ, Patrono C. The role of aspirin in cancer prevention. Nat Rev Clin Oncol 9: 259–267, 2012. doi:10.1038/nrclinonc.2011.199.
44. Tormoen GW, Cianchetti FA, Bock PE, McCarty OJ. Development of coagulation factor probes for the identification of procoagulant circulating tumor cells. Front Oncol 2: 110, 2012. doi:10.3389/fonc.2012.00110.
45. Whiteheart SW. Platelet granules: Surprise packages. Blood 118: 1190–1191, 2011. doi:10.1182/blood-2011-06-359836.
46. Xu XM, Sansores-Garcia L, Chen XM, Matijevic-Aleksic N, Du M, Wu KK. Suppression of inducible cyclooxygenase 2 gene transcription by aspirin and sodium salicylate. Proc Natl Acad Sci USA 96: 5292–5297, 1999. doi:10.1073/pnas.96.9.5292.